Emerging data demonstrate promising results of related haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HCT) for the treatment of hematologic malignancies. Data about G-CSF primed PBSC as reliable source of graft with myeloablative conditioning are lacking. We updated the outcomes in 130 adult patients with high-risk hematologic malignancies who received haplo-PBSC transplantation consecutively under busulfan-based conditioning. PBSC were freshly isolated and infused without ex vivo T-cell depletion into the recipients. Myeloid recovery was achieved in 99.2% patients with full donor chimerism. The cumulative incidence of acute grade 3-4 GvHD, overall and extensive chronic GvHD was 14.9%, 38.6% and 16.5%, respectively. The 3-year non-relapse mortality rate was 24.1%. Non-remission prior to transplant was associated with higher incidence of relapse (P = 0.006), inferior overall survival (P = 0.017) and leukemia-free survival (P = 0.024). These data suggest that PBSC is a reliable graft source in haploidentical, unmanipulated transplant settings under myeloablative conditioning in patients with high-risk hematologic malignancies.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is an effective, even curative, treatment for patients with high-risk hematologic malignancies. Haploidentical donor family members are readily available for allo-HCT recipients who lack HLA-matched related or unrelated donors. Transplantation from haploidentical donors (haplo-HCT) has been applied with promising results for the treatment of hematologic malignancies in the past two decades. [1] [2] [3] [4] Bone marrow (BM), G-CSF-primed PBSCs, G-CSFprimed BM (G-BM) or the combination of PBSCs and G-BM can serve as stem cell sources for allo-HCT. Compared with BM cells, PBSCs used as grafts do not require red blood cell or plasma depletion when the blood groups are mismatched and PBSCs contain more mature T cells than the BM. Most of the trials comparing matched related donor BM (BMT) and PBSC transplantation (PBSCT) showed no significant difference between these two stem cell sources with regard to outcomes. 5 In some trials, a more rapid neutrophil recovery, a higher incidence of GvHD, and a lower incidence of disease recurrence in high-risk leukemia were noted in patients who received PBSCT compared with those who received BMT. 6, 7 In cases of matched unrelated transplantation, a lower risk of graft failure and a higher risk of chronic GvHD occurred in patients who received PBSCT compared with those who received BMT. 8 The impact of different stem cell sources on transplantation outcomes may change with different conditioning regimens, graft manipulation, strategies for the prophylaxis and treatment of GvHD or relapse. The optimal source of stem cells for unmanipulated (without ex vivo T-cell depletion) haplo-HCT under myeloablative conditioning remains uncertain. Unmanipulated G-BM transplantation from haploidentical donors achieved encouraging results in patients with high-risk leukemia. 9 However, the heterogeneity of the diagnoses and conditioning regimens in this study made it difficult to evaluate the detailed impact of G-BM on the outcomes. The graft used in the protocol from Peking University for unmanipulated haplo-HCT with intensive immunosuppression was a combination of G-BM and PBSCs. Updated data for 756 patients with leukemia after a 9-year follow-up confirmed the reliability of this protocol. 3 The use of PBSCs for unmanipulated haplo-HCT (haplo-PBSCT) and its short-term efficacy and safety have been reported for patients with hematologic malignancies. [10] [11] [12] The long-term outcomes of unmanipulated haplo-PBSCT, based on large numbers of patients, have not been determined. We initiated the study of unmanipulated haplo-PBSCT for the treatment of high-risk hematologic malignancies in 2007. In this study, we analyzed the most recent outcomes of 130 consecutive adult patients who received haplo-PBSCT. The data from the 21 cases reported earlier have been updated in this manuscript.
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MATERIALS AND METHODS Patients
A total of 130 patients with high-risk hematologic malignancies without matched related or unrelated donors received haplo-PBSCT between July of 2007 and August of 2015 at the Chinese PLA General Hospital, Beijing, China. The outcomes of 21 of these patients were reported in 2012 and these patients were followed up in this study. The Institutional Review Board of the Chinese PLA General Hospital approved this study. All of the patients and their donors provided written informed consent. The overall characteristics of the patients and donors are summarized in Table 1. HLA typing, donor selection and stem cell harvest Donors were preferentially ranked according to HLA-matched loci, younger age, male sex and better performance status. The donors were s.c. administered rhG-CSF (Filgrastim, Kirin, Tokyo, Japan; 5 μg/kg per day). On the fifth day (day 01) of mobilization, PBSCs were collected. The 6th day of PBSC collection was needed until the target values for mononuclear cells (MNCs,45 × 10 8 /kg of recipient weight) and CD34+ cells (42 × 10 6 /kg of recipient weight) were reached. The unmanipulated PBSCs alone as a graft source were infused into the recipient on the day of collection. The surface markers of the graft PBSCs were determined by multi-color flow cytometry after staining using specific monoclonal antibodies against CD34+, CD3+, CD4+ and CD8+ antigens.
Conditioning regimen and GvHD prophylaxis
The conditioning regimen busulfan cyclophosphamide (BuCy) consisted of the i.v. administration of busulfan (3.2 mg/kg per day on days − 10 to − 8), 1,3-bis(2-chloroethyl)-1-nitrosourea (Carmustine; 250 mg/m 2 once on day − 5), cytarabine (4 g/m 2 per day on days − 7 to − 6), cyclophosphamide (60 mg/kg per day on days − 4 to − 3) and ATG (Thymoglobuline, rabbit; Genzyme Europe BV; 2.5 mg/kg per day on days − 5 to − 2). The FB regimen consisted of fludarabine (30 mg/m 2 per day administered iv on days − 7 to − 3), busulfan and ATG as in the BuCy regimen. TBICy consisted of TBI at a dose of 80 cGy on day − 7 plus busulfan and ATG as in the BuCy regimen. All transplant recipients received cyclosporine A (CsA), mycophenolate mofetil and short-term methotrexate for GvHD prophylaxis. 13 Infection prevention and supportive care
All patients received antibiotic prophylaxis with oral trimethoprimsulfamethoxazole to prevent infection by Pneumocystis carinii from day − 10 to +180, fluconazole for prophylaxis against Candida albicans infection from day − 10 to +70, acyclovir for prophylaxis against HSV and Varicella zoster virus infection from day +1 to the time of CsA discontinuation and ciproflaxacin for intestinal decontamination. Ganciclovir (5 mg/kg) was administered i.v. twice daily from days − 10 to − 2 for prophylaxis of CMV infection. After the infusion of graft cells, patients were monitored weekly by CMV-DNA testing. Patients with CMV antigenemia were treated with either Ganciclovir or Foscarnet. All blood products were irradiated at a dose of 2500 cGy before infusion. G-CSF (5 μg/kg per day, s.c.) was administered to all recipients from day 3 after transplantation until BM myeloid cell recovery.
Relapse monitoring, prophylaxis, intervention and treatment At 1, 2, 3, 6, 9, 12, 24 and 36 months after transplant, the minimal residual disease (MRD) targets and reconstitution of CD3+, CD4+, CD8+ and CD56+ cells were regularly monitored. Imatinib (Novartis, Basel, Switzerland) prophylaxis was initiated for patients with Ph-positive ALL after transplantation for the prevention of leukemia relapse when the number of platelets recovered increased above 50 × 10 9 /L. After 3 months since graft infusion, CsA could be tapered to discontinuation in MRD-positive patients until the occurrence of GvHD. When a hematologic relapse of Phnegative malignancy or Ph-positive leukemia resistant to a tyrosine-kinase inhibitor was diagnosed after transplantation, CsA was discontinued and the relapse was treated with chemotherapy followed by a therapeutic donor lymphocyte infusion (DLI) with the patient's consent. The number of CD3+ cells infused for DLI with G-CSF priming was (0.05-0.1) × 10 8 /kg. Any patients with Ph-positive leukemia who experienced a cytogenetic or hematologic relapse after transplant were treated with tyrosine-kinase inhibitor if it had been effective prior to transplantation.
Definitions and assessments 'High-risk' hematologic malignancies were defined as leukemia and lymphoma with the following features: (1) acute leukemia (AL) with the t (9;22), Flt3-ITD mutation or complex cytogenetics regardless of the disease stage; (2) AML during the CR 1 after three or more cycles of induction, ALL in CR1 beyond 4 weeks of induction or AL in CR1 with positive MRD after two cycles of consolidation; (3) AL beyond CR 2 or in non-remission (NR) or CML beyond the first chronic phase; and (4) T-cell lymphoblastic lymphoma resistant to chemotherapy or autologous transplantation. The time after transplantation was recorded as '+' days, and the time prior to transplantation was recorded as ' − ' days. Engraftment and GvHD were assessed as previously described.
14 MRD was documented as abnormal if the BM samples contained 40.01% of leukemia-associated Abbreviations: AML-CR 2 : relapse within 6 months after CR1; AP = accelerated phase; CML-CP1: 2 cases with 315 I mutation; CP = chronic phase; HCT = hematopoietic stem cell transplantation; late response = AML-CR with 3 or more courses of induction or ALL-CR after 4 weeks of induction; mBuCy = modified busulfan cyclophosphamide regimen; mBuF = modified busulfan fludarabine regimen; MNC = mononuclear cells; MRD + = positive MRD during remission with flow cytometry detection; MRD = minimal residual disease; NR = non-remission; TBICy = total body radiation cyclophosphamide regimen.
immunophenotypic patterns in Ph-negative patients with AL or detectable BCR-ABL in patients with Ph-positive ALL or CML. Patients were diagnosed with MRD positivity when MRD was found to be abnormal in two consecutive assessments within 2 weeks. Relapse was defined as hematologic recurrence of the underlying malignancy.
Statistics
The cumulative incidences of neutrophil and platelet recovery, GvHD, nonrelapse mortality (NRM) and relapse were estimated with the competing risks. The probabilities of overall survival (OS) and leukemia-free survival (LFS) were estimated with the Kaplan-Meier method. In univariate analyses, log-rank test was used for the potential risk factors the with Po0.05 considered to be statistically significant. 
RESULTS
Engraftment and graft composition
Sustained myeloid engraftment with full donor chimerism was achieved in 129 patients (99.2%) at a median of 16 (10-26) days. During the follow-up period, 119 patients (91.5%) achieved platelet recovery at a median of 28 (8-207) days, and the other 11 patients failed to achieve platelet recovery until their death. The cumulative incidences of platelet engraftment at days 30, 60 and 90 were 76.2% ± 4.2%, 88.4% ± 3.0% and 90.1% ± 3.0%, respectively. Multivariate analyses showed that donor age ⩾ 46 year was an independent risk factor for delayed platelet engraftment (hazard ratio (HR): 1.7; 95% confidence interval (CI): 1.045-2.814, P = 0.033). GvHD Acute GvHD grade 2-4 occurred in 35 patients (26.9%) at a median of 42 (10-120) days after transplantation, with a cumulative incidence of 33.4% ± 4.8% on day 100 (Figure 1a) . Late-onset acute GvHD was documented in one case. Ten and three patients developed acute GvHD grade 3 and grade 4, respectively, with a cumulative incidence of 14.9% ± 4.0% (Figure 1a) . Ten of these patients were managed with steroids and basiliximab added to CsA, whereas five patients died.
The 103 (79.2%) patients who survived longer than 100 days after transplantation were assessed for chronic GvHD. After a median of 7.9 (3-30) months, 27 patients (26.2%) developed chronic GvHD and 14 of them developed extensive GvHD with cumulative incidences at 3 years of 38.6 ± 7.6% and 16.5% ± 5.0%, respectively (Figure 1b) . Six of the 14 patients with extensive GvHD were alive in disease-free states during the median followup periods of 14 (6-79) months and resumed their normal lives. There was no risk factor for acute or chronic GvHD found in the risk analyses.
Relapse
As of 5 March 2016, a total of 35 (26.9%) patients had relapsed at a median of 99 (29-1165) days after transplantation. Thirty-three patients had hematologic relapse, and two patients had isolated relapse in the central nervous system. Patients in NR/beyond CR 2 had a higher incidence of relapse (HR: 3.17, 95% CI: 1.39-7.21, P = 0.006, Figure 2a ) compared with those in CR 1 /CR 2 prior to transplantation. There was no difference in the median time to relapse between patients who were in CR 1 /CR 2 (147 days: 40-579) or in NR/beyond CR 2 (178 days: 29-1165) prior to transplantation (P = 0.278).
Six of the relapsed patients received chemotherapy with discontinuation of CsA, followed with DLI. Two patients with isolated central nervous system relapse achieved remission after intrathecal chemotherapy and survived for 2225 and 2365 days after relapse (2697 and 2664 days after transplantation), and they are currently free of underlying malignancies. Overall, 31 patients died of disease recurrence.
NRM, complications and recovery of T-cell subsets Twenty-three patients (17.7%) died from transplant-related complications (Table 2 ) at a median of 103 (27-237) days, resulting in a 3-year cumulative incidence of 24.1% ± 4.7%. In the multivariate analyses, a lower NRM was associated with donor age o 46 year (HR: 0.26, 95% CI: 0.09-0.74, P = 0.012, Figure 2b ).
A total of 105 patients (80.9%) developed a fever within the first 30 days after transplantation. Nineteen patients (14.6%) had documented bacteremia. Seventy-seven patients (59.6%) were diagnosed with CMV reactivation and received preemptive anti-CMV therapy, seven of these patients were diagnosed with CMV pneumonia and one was diagnosed with CMV hepatitis. The cumulative incidences of CMV reactivation and CMV disease were 61.0 ± 5.3% and 8.0% ± 2.9% at 1 year post transplantation, respectively. The cumulative incidences of EBV reactivation and post-transplantation lymphoproliferative disease were 40.0 ± 4.2% and 6.0% ± 2.7% at 1 year after transplantation, respectively.
Fifty-seven (43.8%) patients developed hemorrhagic cystitis, with a cumulative incidence of 46.5% ± 5.5% at 6 months after transplantation. Undergoing a second transplant (HR: 10.08, 95% CI: 3.88-26.17, P = 0.000) was found to be a risk factor for hemorrhagic cystitis occurrence.
Eighty-one patients were followed up to determine the reconstitution of T-cell subsets (Table 3 ). There were no correlations found between the numbers of CD3+, CD4+, CD8+ or CD56+ cells at 1, 2, 3 and 6 months and the occurrence of GvHD, relapse, CMV reactivation or NRM.
Survival
As of 5 March 2016, 75 (57.7%) patients were alive, with a median follow-up of 1067 (180-2803) days for survivors without disease recurrence. The 3-year probabilities of OS and LFS were 45.6% ± 5.6% and 44.2% ± 5.9%, respectively. Donor age ⩾ 46 year was associated with a shorter OS (HR: 0.44, 95% CI: 0.22-0.86, P = 0.017, Figure 3a) and LFS (HR: 0.45, 95% CI: 0.22-0.90, P = 0.024, Figure 3b ).
DISCUSSION
This is a report on the use of PBSCs alone as a graft source for unmanipulated haplo-HCT with the GIAC protocol at a single center. The feasibility of PBSCs as a graft source in T-cell-replete haplo-HCT has been demonstrated recently with a reducedintensity conditioning regimen using post-transplantation cyclophosphamide (PT/Cy) 4, [15] [16] [17] in elderly patients with hematologic malignancies. However, its use with myeloablative conditioning has been reported in a limited number of cases. [10] [11] [12] In the current study, all patients were diagnosed with high-risk hematologic malignancies and had received haplo-HCT consecutively in the past decade. After a median follow-up period of 3 years, a rapid, steady neutrophil engraftment with full donor chimerism was recorded in 499% of the patients. The incidences of GvHD grade 3-4 and chronic GvHD were low, with acceptable NRM and survival.
In the current study, the incidence of platelet recovery was similar to that reported by Peking University. In their unmanipulated haplo-HCT with G-BM combined with PBSCs, the risk factors for delayed PLT recovery were found to be advanced leukemia stage and low numbers of CD34+ cells infused in the graft. 18 In the present study, the only risk factor for delayed PLT recovery found by the multivariate analyses was an older donor age. In the univariate analyses, older donor age was associated with lower numbers of CD34+ cells infused in the graft (data not shown). The delay in platelet recovery or prolonged isolated thrombocytopenia remains the main problem of hematopoietic reconstitution after unmanipulated haplo-HCT. 19 Although its mechanism is not clear, choosing a younger donor from the haploidentical family members should be preferred. 20 In allo-HCT from matched sibling donors, trials have shown a significantly higher incidence of acute GvHD grade 2-4, 6,7 chronic GvHD and extensive chronic GvHD 6, 20 in PBSC recipients compared with BM recipients. In matched unrelated transplants, more chronic GvHD (53 vs 41%) and extensive chronic GvHD (48 vs 32%) 21 were documented in PBSC recipients. Furthermore, this difference in GvHD risk between PBSC and BM transplant recipients in unrelated transplantations could be abrogated with the use of ATG for GvHD prophylaxis. 22 It could be postulated that there should be no difference in GvHD risk between G-BM combined with PBSC and PBSC alone recipients after intensive immunosuppressed, unmanipulated haploidentical transplantation using ATG as GvHD prophylaxis. The incidences of acute GvHD grade 2-4, acute GvHD grade 3-4, chronic GvHD and extensive GvHD in Wang's report were 43%, 14%, 53% and 23%, respectively, 3 which are similar to those reported in the present study. Although this is an indirect comparison, the use of ATG during conditioning should have contributed to the low incidence of acute severe GvHD and chronic GvHD in the current study.
Baltimore and other groups developed a method to selectively deplete alloreactive cells in vivo by administering high doses of cyclophosphamide (PT/Cy) after haploidentical transplantation. In their reports using non-myeloablative conditioning, the graft sources were BM 22 or PBSCs. 8, 23 The median age of the patients in their reports ranged from 45 to 55 year, which was much higher than that in our study. The incidences of acute GvHD grade 3-4 (6, 8, 14%) and chronic GvHD (5, 16-18, 13%) in each study were low with acceptable NRM. Another impressive outcome of this PT/Cy setting was that few patients developed a severe infection after transplantation. This method made crossing the HLA barrier possible with haploidentical donors and enabled the transplantation to be performed safely in outpatient clinics. The incidences of acute and chronic GvHD in the present study were also low, which may be associated with the use of ATG and the relatively younger median age of the patients. Except for the advantage of ATG in reducing the occurrence of severe GvHD, it should be noted that the main cause of death in our study was infection. This result suggests that the quality of the immune reconstitution after our current transplantation protocol needs to be improved. In addition, the relatively high rate of graft failure (4%-13%) in the PT/Cy setting seemed to be unacceptable for our young, high-risk patients, although most of the patients who received the non-myeloablative conditioning protocol achieved autologous hematopoietic recovery.
When we restricted the analysis to the patients who were in NR/ beyond CR 2 , we found that one patient with AML-CR3 achieved LFS, eight (33%) of those with AML-NR (n = 24) relapsed and all ALL-NR patients died of relapse (data not shown). In other words, the rate of relapse among patients with AML-NR/beyond CR 2 was 30%, and the prognosis for ALL-NR patients was dismal. In a study by Di Bartolomeo et al. 9 on unmanipulated haplo-HCT with G-BM, the 3-year cumulative incidence of relapse among high-risk patients (beyond CR 2 , n = 35) was 24%. This incidence was relatively low compared with our observations, although it is difficult to evaluate the impact of their transplantation procedure on preventing relapse for each single disease category due to the heterogeneity of diagnoses (leukemia and lymphoma, n = 23). The above observation could be partially associated with the intensified myeloablative conditioning regimen. This hypothesis could be supported by the relatively high NRM (45%) compared with that in our study. The conditioning regimen we used was identical to that used at Peking University. The incidence of disease recurrence in Wang's report was 26% among the patients in the NR/beyond CR 2 stages. Their relatively low incidence of relapse could be attributed to the routine prophylactic DLI used at their center since 2006. In our study, the time to relapse in four of eight AML-NR patients and all ALL-NR patients was 44 months post transplantation, which suggested that there should be a window of time after transplantation to prevent the recurrence of malignancies. Huang et al. 11 reported a low incidence of relapse (15.4%) in high-risk patients. However, it is not reasonable to compare their outcomes with the above outcomes because their definition of 'high-risk' malignancies and the source of ATG (ATG-F; Fresenius, Bad Homburg, Germany, 10 mg/kg) they used were different from those in the above studies. 12 Despite successful engraftment and a low incidence of severe GvHD in our study, relapse remained a problem for the patients who were in NR/beyond CR 2 prior to transplantation. Strategies under investigation to prevent relapse include prophylactic modified DLI, the use of interferon, the infusion of specific cytotoxic T cells and optimizing the dose of ATG. In conclusion, our data demonstrated the reliability of G-CSF-primed PBSCs as a graft source in unmanipulated haplo-HCT under myeloablative conditioning. In addition, our study extended the stability of haploidentical, unmanipulated transplant protocols with intensive, successive immunosuppression. 
